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Since the first description of the immunologic
mechanisms in neonatal and thrombocytopenic
purpura1 and the first report of a maternal antibody
directed against a platelet alloantigen inherited from
the father,2 in the 1950s, much has been learned
concerning fetal and neonatal alloimmune
thrombocytopenia (FNAIT), but questions are still
unanswered. FNAIT has been regarded as the platelet
counterpart of HDN, but, in contrast to HDN, the first
infant is affected in 50 percent of cases. This condition,
which has been estimated to have an incidence of 1 in
800 to 1 in 1000 live births,3,4 can cause severe
bleeding in the fetus and newborn, and all
incompatible fetuses will be at risk for subsequent
pregnancies. Therefore, it is important to diagnose
FNAIT and to manage the subsequent pregnancies to
prevent the consequences of severe fetal
thrombocytopenia.
1953–2007: the Platelet Alloantigen Story
Over the years, considerable progress has been
made in the characterization of platelet-specific
alloantigens. Improvements in serologic methods for
the detection of maternal alloantibodies—including
the use of antigen-capture assays, the monoclonal
antibody-specific immobilization of platelet antigens
technique,5 or monoclonal antigen capture ELISA6—
the development of immunochemical techniques, and
the advent of molecular biological techniques have led
to the description of 24 platelet-specific alloantigens.
A human platelet antigen (HPA) nomenclature was
adopted in 1990 to replace the lab-specific
nomenclature that was used previously. The antigenic
systems are numbered in order of the date of
discovery; the high-incidence allele is called“a,”and the
low-incidence allele is called “b” in the original
population in which the alleles were identified.7 Under
the auspices of the International Society of Blood
Transfusion and the International Society of
Thrombosis and Haemostasis, a Platelet Nomenclature
Committee has published tables that will be updated;
these include the list of the HPA antigens, the antigen
genetic basis, and the platelet antigen alleles defined by
sequencing. The HPA nomenclature will still be used
for clinical and scientific purposes.8 The reader is
referred to the table of numbered HPAs, their
glycoprotein location, and approximate Caucasian
phenotype frequencies in “Scott Murphy’s contri-
butions in the early years of posttransfusion purpura: a
remembrance” in this issue of Immunohematology.
HPA antigens are expressed on different integrins
playing a role in cellular interactions. α2bβ3 (GPIIb−IIIa)
is the major platelet integrin and is restricted to
platelets, whereas the αvβ3 integrin is expressed more
widely. α2bβ1, also known as GPIa-IIa, is the second
most important platelet integrin and is also found on
lymphocytes. Antigens located on β3 (GPIIIa) have
been found on other cells, such as endothelial cells, and
on activated T lymphocytes when located on α2; this
may play a pathophysiologic role.
Frequencies of platelet antigens vary among
different populations. In Caucasians, HPA-1a is by far
the most common antigen implicated in FNAIT,9
followed at much lower frequency by HPA-5b,10 then
HPA-3.11 In contrast, in Asians, FNAIT is essentially
associated with HPA-4 and HPA-5b. FNAIT has been
reported involving rare or private antigens.8 Recent
studies have shown that these low-frequency antigens
are not restricted to single families,12 especially anti-
HPA-9bw, which could account for up to 2 percent of
confirmed cases13,14; therefore they must not be ignored
in the screening for FNAIT with a negative initial
laboratory investigation. The humoral maternal
response is not uniform in this condition and must be
taken into account when undertaking serologic
diagnosis.15 Further study of the characteristics of the
maternal alloantibodies and their relevance to the
clinical condition would be of interest.16
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The genetic basis for maternal alloimmunization
has been investigated. Alloimmunization to the HPA-1a
antigen appears to be associated with HLA class II
alleles: DRB3*0101 and DQB1*0201 (odds ratio 24.9
and 39.7, respectively).17,18 An anti HPA-1b response
was not associated with either DRB3*0101 or any
known HLA class II molecules.19 This finding implies
the Leu33/Pro33 substitution on the platelet
glycoprotein IIIa plays a role in antigen presentation.
Data have shown that the binding of peptides from the
Leu33/Pro33 dimorphic region to HLA-DR3*0101 is
allele specific with stimulation of specific T cells20,21
providing help to B cells for generating alloantibodies;
however, the positive predictive value is only 35
percent, and utility for screening is therefore limited.
The immune response to HPA-5b antigen is
strongly associated with a particular DRB1 gene
sequence encoding residues Glu-Asp at positions 69
and 70 of the DRβ chain.22 For other antigens, because
of the low number of cases, statistical analyses are not
significant when compared with the general
population, as seen for HPA-6b and DRB1*1501,
DQA1*0102, DQB1*0602 haplotypes shared by
immunized mothers.23
1953–2007: the Fetal and Neonatal
Alloimmune Thrombocytopenia Story
Natural history
FNAIT has been known for decades as “neonatal
alloimmune thrombocytopenia” (NAIT). The usual
presentation is a full-term neonate exhibiting petechiae
or widespread purpura at birth, or a few hours after
birth, to a healthy primiparous mother. Otherwise, this
infant is well with no clinical signs of infection
(hepatosplenomegaly) or malformation (hemangioma,
absence of radii). Visceral hemorrhages such as
gastrointestinal bleeding or hematuria are less common
than purpura or hematoma. The thrombocytopenia is
isolated. Coexisting anemia is caused by hemorrhage.
Anti-HPA-1a and anti-HPA-3a immunization induce
severe neonatal thrombocytopenia with platelet
counts less than 50 × 109/L in most cases.9,11 NAIT
linked to HPA-5b incompatibility seems to be less
severe than HPA-1a NAIT.10 The most serious
complication is fetal or neonatal intracranial
hemorrhage (ICH; 25.5% of cases for HPA-1a, 24% for
HPA-3a, 15% for HPA-5b)24 leading to death in up to 10
percent or neurologic sequelae in up to 20 percent of
reported cases.
The risk of life-threatening hemorrhage
necessitates prompt diagnosis and effective therapy.
Phenotyped platelet transfusion is the best postnatal
management. Because of the logistic difficulties in
obtaining such platelets in emergency situations,
random platelet transfusions with or without IVIG have
been proposed.25 However, compatible platelets give
better results.26 On the other hand, thrombocytopenia
may be asymptomatic and pass unnoticed unless there
is a routine platelet count performed. Therefore,
unexpected or unexplained neonatal thrombo-
cytopenia or severe early onset thrombocytopenia in
both preterm and term babies should raise the
possibility of NAIT and guide investigations
accordingly. The fetal thrombocytopenia tends to
worsen in subsequent incompatible pregnancies.
Fetal blood sampling
In 1983, a major advance in the diagnosis of NAIT
was the use of ultrasound-guided fetal blood sampling
(FBS), which led to a better understanding of the fetal
status.27 The mean platelet count has been evaluated to
be more than 150 × 109/L by the end of the first
trimester of pregnancy in healthy fetuses and similar to
the adult platelet count later on. Therefore, thrombo-
cytopenia has been defined in the fetus and the
neonate as a platelet count less than 150 × 109/L,
irrespective of the gestational age.28
In 1984, the first fetal alloimmune thrombo-
cytopenia case was documented with FBS at 32 weeks
of gestation, and in utero maternal platelet transfusion
before delivery was proposed as therapy to avoid
perinatal ICH.29 Severe fetal thrombocytopenia was
then documented early during pregnancy when FBS,
as part of the antenatal management protocol, was
carried out at 21 weeks of gestation for subsequent
pregnancies in women with a previously affected
infant.30 A retrospective survey of 5194 fetal blood
samplings showed that fetal thrombocytopenia
resulting from maternal alloimmunization was the
most severe thrombocytopenia observed among the
different disorders encountered, including chromo-
somal malformations, infections, or maternal
autoimmune thrombocytopenia.31
Development of antenatal management
The rationale for antenatal management is the
high rate of recurrence for subsequent incompatible
fetuses who usually experience more severe thrombo-
cytopenia. The first attempts to prevent severe
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thrombocytopenia in the preterm period and thus ICH
during delivery were in utero platelet transfusions
before delivery.30 However, this management could not
prevent in utero ICH, which has been reported
primarily before 30 weeks of gestation.24 Because of
the short survival of transfused platelets, weekly fetal
platelet transfusions have been proposed and shown to
be effective in preventing ICH in a number of cases.32
The risks of in utero platelet transfusion, bleeding, and
fetal loss have been estimated to be 1 to 2 percent per
procedure and 8 percent per pregnancy.33 Fetal cardiac
arrhythmia (prolonged bradycardia) has also been
reported. Less invasive therapy has also been
proposed, involving maternal administration of IVIG,
steroids, or both.
The mechanism of action of IVIG is complex,
including inhibition of the transplacental passage of
maternal alloantibodies and modification of the
immune response. Corticosteroids may modulate the
maternal immune response. Different IVIG protocols
have been developed and differences in results were
reported mainly because of the definition of a
successful response.34–36 Low-dose corticosteroids, as
sole therapy, have been given to a limited number of
patients, and response to therapy appears highly
variable.35
The optimal management remains to be
determined, and an international forum in 2003
demonstrated the absence of standardization.37
The decision regarding therapy depends on
different factors, among which the fetal status plays a
central role. There is no reliable and sensitive
parameter for predicting which fetuses will be severely
affected and which ones will respond to therapy. The
only way to assess the fetal status is to perform FBS,but
the risk of serious adverse events from this technique
is high, up to 10 percent.38 Most protocols favor
maternal therapy with less invasive strategies39,40 with
stratification according to the previously affected
sibling’s status.41
Serial in utero platelet transfusions are considered
only as salvage therapy after failure of maternal
treatment.
Antenatal screening
No systematic screening for FNAIT exists at the
moment, and this condition is still underdiagnosed.42
Reduction of neonatal death and disability is a public
health issue, and recent progress in the prevention of
current causes of neonatal disorders has been efficient
at reducing the risk of neonatal disorders going
undiagnosed and untreated. Prospective studies have
shown that although 2 to 3 percent of women are at
risk for developing anti-HPA immunization, only 1 in
800 to 1000 newborns will be affected.3,4,43 It has been
found that 26 percent of infants born to immunized
mothers are nonthrombocytopenic. Until procedures
are found that predict which women will have an
affected fetus, maternal screening has a low sensitivity.
Only identifying thrombocytopenic newborns at birth
increases the sensitivity but will miss fetuses severely
affected during pregnancy who should have been
treated. Cost-effectiveness analysis indicated screening
newborns was more cost-effective than screening
primiparous women.3 A consensus on routine investi-
gation and optimal antenatal management has yet to be
reached.
Future Directions
Although real progress has been achieved in the
more accurate diagnosis and management of FNAIT,
further studies must focus on improvements in
antenatal management and on mechanisms of
maternal sensitization. A recent study has shown that
high maternal anti-HPA-1a alloantibody concentrations
may provide an indication of severely affected fetuses44
and this may contribute to a less invasive antenatal
therapeutic strategy. However, the follow-up of mater-
nal anti-HPA-1a concentration during pregnancy should
not be considered as an indicator of therapeutic
effectiveness.
A murine model has also been recently developed,
which may contribute to a better understanding of this
condition in the future.45
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